Blood Cancer Drugs Global Market Report 2022 – By Blood Cancer Type (Leukemia, Lymphoma), By Drugs (Rituaxan/Mabthera: Rituximab), Gleevac/Glivec: Imatinib), Revlimid: Lenalidomide), Velcade: Bortezomib), Tasigna: Nilotinib), Pomalyst: Pomalidomide), Vidaza: Azacitidine), Kyprolis: Carfilzomib), Adcetris: Brentuximab Vedotin)), By Treatment Approaches (Key Findings, Chemotherapeutic, Mabs/Targeted Therapies, Immunotherapeutic) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 175 | Published : March 2022 | SKU CODE : 7215 | Delivery Time: 2-3 business days | Format :


The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukaemia, lymphoma, and myeloma.

The main types of blood cancer drugs are leukemia, and lymphoma. Leukemia is a blood-forming tissue cancer that affects the bone marrow and lymphatic tract. The different types of drugs include rituaxan/mabthera (rituximab), gleevac/glivec (imatinib), revlimid (lenalidomide), velcade (bortezomib), tasigna (nilotinib), pomalyst (pomalidomide), vidaza (azacitidine), kyprolis (carfilzomib), adcetris (brentuximab vedotin), others and involve various treatment approaches such as key findings, chemotherapeutic, mabs/targeted therapies, immunotherapeutic.

The global blood cancer drugs market size is expected to grow from $54.83 billion in 2021 to $61.26 billion in 2022 at a compound annual growth rate (CAGR) of 11.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global blood cancer drug market size is expected to reach $89.75 billion in 2026 at a CAGR of 10.0%.

The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukaemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukaemia, and 275,047 cases myeloma. Furthermore, the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, more than 387,000 people are living with leukaemia in the United States and 68,000 deaths resulted from blood cancer. According to national cancer institute, the deaths due to blood cancer reached around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drug market.

Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials are also high as clinical trial phases involves huge investments. According to Tufts Centre for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion. Thus indicating that the high drug approval costs hinders the growth of the blood cancer drugs market.

Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyse large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

The Food and Drug Administration (FDA) is a federal agency regulating the blood cancer drugs market. In June 2019, FDA declined to approve Daiichi Sankyo’s leukaemia drug for blood cancer treatment. Daiichi Sankyo, a global pharmaceutical company developing, importing and marketing pharmaceutical products received a rejection notice on its drug - quizartinib used for treating adults with a type of blood cancer. The rejection of drug was due to the negative impact caused after the intake which resulted in FDA's statement saying faulty application for blood cancer treatment in an internal review. To avoid the incidences caused by such medicines in treating medical conditions such as blood cancer, FDA has declined to the approval.

In 2019, Eli Lilly, a US-based pharmaceutical company, acquired Loxo Oncology, a cancer-focused biotechnology company for $8 billion. This acquisition of Loxo Oncology provides Lilly with a promising pipeline of investigational medicines such as oral RET inhibitor, oral BTK inhibitor and others. The deal would enable Lilly to attain strong patent on Loxo's genetically based approach to treat cancer. Loxo Oncology, is a biopharmaceutical company, developing and selling medicines for patients with genetically defined cancers. The company focuses on building small molecule cancer drugs for genetically defined cancer patients. The company was founded in 2013 and is headquartered in Stamford, Connecticut, USA.

Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc. and Takeda Pharmaceutical Company Ltd.

North America is the largest region in the blood cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global blood cancer drug market during the forecast period. The regions covered in the global blood cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the blood cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global blood cancer drugs market is segmented -

1) By Blood Cancer Type: Leukemia, Lymphoma

2) By Drug: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others

3) By Treatment Approach: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic

    Table Of Contents

    1. Executive Summary

    2. Blood Cancer Drugs Market Characteristics

    3. Blood Cancer Drugs Market Trends And Strategies

    4. Impact Of COVID-19 On Blood Cancer Drugs

    5. Blood Cancer Drugs Market Size And Growth

    5.1. Global Blood Cancer Drugs Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Blood Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Blood Cancer Drugs Market Segmentation

    6.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Leukemia

    Lymphoma

    6.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

     Rituaxan/Mabthera (Rituximab)

    Gleevac/Glivec (Imatinib)

    Revlimid (Lenalidomide)

    Velcade (Bortezomib)

    Tasigna (Nilotinib)

    Pomalyst (Pomalidomide)

    Vidaza (Azacitidine)

    Kyprolis (Carfilzomib)

    Adcetris (Brentuximab Vedotin)

    Others

    6.3. Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Key Findings

    Chemotherapeutic

    mAbs/Targeted Therapies

    Immunotherapeutic

    7. Blood Cancer Drugs Market Regional And Country Analysis

    7.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Blood Cancer Drugs Market  

    8.1. Asia-Pacific Blood Cancer Drugs Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Blood Cancer Drugs Market  

    9.1. China Blood Cancer Drugs Market Overview  

    9.2. China Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Blood Cancer Drugs Market  

    10.1. India Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Blood Cancer Drugs Market  

    11.1. Japan Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Blood Cancer Drugs Market  

    12.1. Australia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Blood Cancer Drugs Market  

    13.1. Indonesia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Blood Cancer Drugs Market  

    14.1. South Korea Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Blood Cancer Drugs Market  

    15.1. Western Europe Blood Cancer Drugs Market Overview

    15.2. Western Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Blood Cancer Drugs Market  

    16.1. UK Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Blood Cancer Drugs Market  

    17.1. Germany Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Blood Cancer Drugs Market  

    18.4. France Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Blood Cancer Drugs Market  

    19.1. Eastern Europe Blood Cancer Drugs Market Overview

    19.2. Eastern Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Blood Cancer Drugs Market  

    20.1. Russia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Blood Cancer Drugs Market  

    21.1. North America Blood Cancer Drugs Market Overview

    21.2. North America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Blood Cancer Drugs Market  

    22.1. USA Blood Cancer Drugs Market Overview

    22.2. USA Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Blood Cancer Drugs Market  

    23.1. South America Blood Cancer Drugs Market Overview

    23.2. South America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Blood Cancer Drugs Market  

    24.1. Brazil Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Blood Cancer Drugs Market  

    25.1. Middle East Blood Cancer Drugs Market Overview

    25.2. Middle East Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Blood Cancer Drugs Market  

    26.1. Africa Blood Cancer Drugs Market Overview

    26.2. Africa Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Blood Cancer Drugs Market Competitive Landscape And Company Profiles

    27.1. Blood Cancer Drugs Market Competitive Landscape

    27.2. Blood Cancer Drugs Market Company Profiles

    27.2.1. Amgen Inc.

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. AstraZeneca PLC

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Bayer AG

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Celgene Corporation

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Eli Lilly

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Blood Cancer Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Blood Cancer Drugs Market

    30. Blood Cancer Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: Amgen Inc. Financial Performance
  • Table 47: AstraZeneca PLC Financial Performance
  • Table 48: Bayer AG Financial Performance
  • Table 49: Celgene Corporation Financial Performance
  • Table 50: Eli Lilly Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: Amgen Inc. Financial Performance
  • Figure 47: AstraZeneca PLC Financial Performance
  • Figure 48: Bayer AG Financial Performance
  • Figure 49: Celgene Corporation Financial Performance
  • Figure 50: Eli Lilly Financial Performance
Global Contract Research And Manufacturing Services (CRAMS) Market Size, Forecasts, And Opportunities – Includes CRAMS Market Overview
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Cancer Diagnostics Global Market Report 2022 – By Products (Companion Diagnostics, Molecular Diagnostics), By End-User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users), By Method (Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging), By Application (Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Brain Tumor Drugs Market 2022 - By Drugs (Temozolomide, Bevacizumab), By End User (Hospital Pharmacies, Retail Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Breast Cancer Drugs Global Market Report 2022 – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Others: Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy), By Drug Type (Her2 Inhibitors, Mitotic Inhibitors, Anti-Metabolites, Aromatase Inhibitors, Hormonal Receptor), By End User (Amubulatory, Hospitals, Clinics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Skin Cancer Drugs Global Market Report 2022 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By End Users (Hospitals, Cancer Research Centers, Clinics), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cervical Cancer Diagnostics Global Market Report 2022 – By Diagnostic Test (Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Other Diagnostic Tests), By Age Group (Below 21, Age between 21 to 29, Age between 30 to 65, Above 65), By End-User (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres, Diagnostic Centres) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Prostate Cancer Drugs Global Market Report 2022 – By Type (Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer), By Therapy (Hormonal Therapy, Chemotherapy , Immunotherapy, Targeted Therapy), By End User (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Ovarian Cancer Drugs Global Market Report 2022 – By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor), By Distribution Channel (Hospital Pharmacies, Drug Stores, Others), By Drug Type (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors, Antineoplastics, Others) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cancer Vaccines Global Market Report 2022 – By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines), By Cancer Type (Prostate, Cervical, Colorectal, Throat), By End-User (Cancer Treatment Centers, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report